STAT6 and neoplasm: designed a micellar nanodrug carrier for delivering IκB kinase‐β (IKKβ) siRNA and STAT6 inhibitor AS1517499 (AS), and modified with a M2pep to target M2‐like TAMs for treatment of 4T1 breast tumor.[116] The resultant ST‐AS&Si nanodrug down‐regulated the expressions of IKKβ (a critical upstream factor controlling NF‐κB activation) and phospho‐STAT6 (p‐STAT6) in M2‐like macrophages, thereby repolarizing them into tumor‐killing M1 phenotype.